Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Source: SeekingAlpha
2025-12-11 13:52:58 ET
Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma December 11, 2025 9:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript
Scancell Holdings Plc Ord
NASDAQ: SCNLF
SCNLF Trading
-1.1% G/L:
$0.1975 Last:
52,000 Volume:
$0.1997 Open:
SCNLF Latest News
January 26, 2026 02:00:00 am
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
SCNLF Stock Data
$182,634,338
524,536,083
16.2%
N/A
Biotechnology & Life Sciences
Healthcare
GB
Oxford
